PHARMacist tool for Achieving A1C Targets with Fixed Ratio Combination Therapy (PHARM A1C-Fix)





# of Credits




Expiry Date


Fixed Ratio Combinations (FRC) of basal insulin and GLP-1 receptor agonists (GLP-1 RA) provide patients with type 2 diabetes a combination of two injectable antihyperglycemic agents with complementary mechanisms of action in a single injection.

The use of FRC has been shown to be more effective than either component alone with a lower risk of adverse effects for both basal insulin and GLP-1 RA.


Alexander Abitbol, MDCM, FRCPC Ronald M. Goldenberg, MD, FRCPC, FACE Alicia Chin, RPh Carlene Oleksyn, B.S.P. Pharm, CTH™

Upon completion of this continuing education program, pharmacists will be better able to: 1. Determine which patients with type 2 diabetes will likely benefit most from the use of a fixed-ratio combination (FRC) of basal insulin and GLP-1 RA 2. Review key studies supporting the role of FRC in patients with type 2 diabetes 3. Examine the benefits of using FRC when selecting injectable therapies for type 2 diabetes 4. Counsel a patient on the efficacy, safety, and administration of FRC

Related Courses